0000000000726591

AUTHOR

Filippo Crea

0000-0002-9482-411x

showing 3 related works from this author

Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era

2020

Abstract Aims To evaluate the impact of the COVID-19 pandemic on patient admissions to Italian cardiac care units (CCUs). Methods and Results We conducted a multicentre, observational, nationwide survey to collect data on admissions for acute myocardial infarction (AMI) at Italian CCUs throughout a 1 week period during the COVID-19 outbreak, compared with the equivalent week in 2019. We observed a 48.4% reduction in admissions for AMI compared with the equivalent week in 2019 (P < 0.001). The reduction was significant for both ST-segment elevation myocardial infarction [STEMI; 26.5%, 95% confidence interval (CI) 21.7–32.3; P = 0.009] and non-STEMI (NSTEMI; 65.1%, 95% CI 60.3–70.3; P …

MaleMyocardial Infarction030204 cardiovascular system & hematologySettore MED/110302 clinical medicineAcute myocardial infarction Cardiac care units STEMI Aged Aged 80 and over COVID-19 Female Hospitalization Humans Italy Male Middle Aged SARS-CoV-2 Betacoronavirus Coronavirus Infections Myocardial Infarction Pandemics Pneumonia ViralCase fatality rate80 and overMedicine030212 general & internal medicineMyocardial infarctionViralAged 80 and overAcute myocardial infarction; Cardiac care units; COVID-19; SARS-CoV2; STEMI; Aged; Aged 80 and over; Female; Hospitalization; Humans; Italy; Male; Middle Aged; Betacoronavirus; Coronavirus Infections; Myocardial Infarction; Pandemics; Pneumonia ViralMiddle AgedHospitalizationItalyFemaleCardiology and Cardiovascular MedicineCoronavirus InfectionsHumanmedicine.medical_specialtyPneumonia ViralFast Track Clinical ResearchCardiac care unitsAcute myocardial infarctionSTEMI03 medical and health sciencesBetacoronavirusCardiac care unitHumansAcute myocardial infarction; COVID-19; Cardiac care units; SARS-CoV2; STEMIcardiovascular diseasesPandemicsAgedBetacoronaviruPandemicbusiness.industryCoronavirus InfectionSARS-CoV-2COVID-19Pneumoniamedicine.diseaseacute myocardial infarction; cardiac care units; COVID-19; SARS-CoV2; STEMIConfidence intervalRelative riskEmergency medicineSettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARESARS-CoV2Myocardial infarction complicationsObservational studyMyocardial infarction diagnosisbusinessComplication
researchProduct

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

2020

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

unstable anginaMyocardial ischaemia[SDV]Life Sciences [q-bio]Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]dual antithrombotic therapyGuidelineheparin030204 cardiovascular system & hematologyPlatelet inhibitionantiplatelet0302 clinical medicineST segmentMedicinedabigatranMyocardial infarctionguidelinesglycoprotein iib/iiia inhibitorsanticoagulationNon-ST Elevated Myocardial InfarctionrivaroxabanComputingMilieux_MISCELLANEOUSreproductive and urinary physiologydiabetesbleedingsbivalirudinatherothrombosiDisease ManagementangioplastyGuidelines • acute cardiac care • acute coronary syndrome • angioplasty • anticoagulation • antiplatelet • apixaban • aspirin • atherothrombosis • betablockers • bleedings • bivalirudin • bypass surgery • cangrelor • chest pain unit • clopidogrel • dabigatran • diabetes • dual antithrombotic therapy • early invasive strategy • edoxaban • enoxaparin • European Society of Cardiology • fondaparinux • glycoprotein IIb/ IIIa inhibitors • heparin • high-sensitivity troponin • minoca • myocardial ischaemia • myocardial infarction • nitrates • non-ST-elevation myocardial infarction • platelet inhibition • prasugrel • recommendations • revascularization • rhythm monitoring • rivaroxaban • stent • ticagrelor • triple therapy • unstable anginaenoxaparinGeneral MedicineClopidogrel3. Good healthearly invasive strategymyocardial infarctiontriple therapy030220 oncology & carcinogenesisHigh sensitivity troponinembryonic structuresCardiologyPlatelet aggregation inhibitorrevascularizationbiological phenomena cell phenomena and immunityCardiology and Cardiovascular MedicineTicagrelormedicine.drugHumanrecommendationAcute coronary syndromemedicine.medical_specialtyaspiringlycoprotein IIb/IIIa inhibitornon-ST-elevation myocardial infarctionapixabanrhythm monitoringEuropean Society of Cardiologyticagrelor03 medical and health sciencesnitrateatherothrombosisbetablockersInternal medicineacute cardiac careminocachest pain unitDiseases of the circulatory (Cardiovascular) systemHumansIn patientAcute Coronary SyndromeclopidogrelUnstable anginaurogenital systemnitratesbusiness.industryfondaparinuxbetablockerArrhythmias Cardiac030229 sport sciencesbleedingmedicine.diseasemyocardial ischaemiaplatelet inhibitionprasugreldiabeteGlycoprotein IIb/IIIa inhibitorsRC666-701bypass surgerySettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARErecommendationsedoxabanhigh-sensitivity troponinstentbusinessPlatelet Aggregation Inhibitorscangrelor
researchProduct

Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management

2020

Currently, there is no effective therapy for COVID-19, and several approaches are under investigation. Nevertheless, some drugs are used off-label despite the absence of clear data on their effectiveness. Among these, hydroxychloroquine suppresses SARS-CoV-2 replication in vitro,1 and clinical trials are ongoing to evaluate its use as an anti-COVID-19 agent. To date, the FDA and EMA allow its use only in hospitalized patients with severe COVID-19 or in those at high risk, in cases where other trials are not feasible. According to a small non-randomized study, hydroxychloroquine’s efficacy might be enhanced by azithromycin, as the combination of these two drugs appeared to accelerate viral c…

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINECOVID-19MinocyclineMinocyclineAzithromycinAzithromycinAnti-Bacterial AgentsCOVID-19 Drug TreatmentSettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARECorrespondenceHumansMedicinePharmacology (medical)Cardiology and Cardiovascular MedicinebusinessIntensive care medicineCOVID 19medicine.drugEuropean Heart Journal - Cardiovascular Pharmacotherapy
researchProduct